2. Signaling Pathways
  3. Anti-infection
  4. Endoplasmic Reticulum Oxidoreductase 1 (ERO1)
  5. Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Inhibitor

Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Inhibitor

Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-14852
    Tafamidis
    		Inhibitor 99.89%
    Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.
  • HY-12837
    EN460
    		Inhibitor 99.94%
    EN460 is a selective endoplasmic reticulum oxidation 1 (ERO1) inhibitor. EN460 (IC50 of 1.9 μM) interacts selectively with the reduced, active form of ERO1α and prevents its reoxidation.
  • HY-148520
    QM295
    		Inhibitor 98.53%
    QM295 is an endoplasmic reticulum oxidation 1 (ERO1) inhibitor with selectively reversible thiol reactivity. QM295 can be used for the research of endoplasmic reticulum stress.
  • HY-175593
    M6766
    		Inhibitor
    M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC50 of 1.4 μM and a KD of 1.1 μM. M6766 also inhibits ERO1β with an IC50 of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca2+ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke.
  • HY-14852R
    Tafamidis (Standard)
    		Inhibitor
    Tafamidis (Standard) is the analytical standard of Tafamidis. This product is intended for research and analytical applications. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.